Titre | Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder |
Type de publication | Article de revue |
Auteur | Leroux, Pierre-Adrien, Brassart, Elena, Lebdai, Souhil , Azzouzi, Abdel Rahmene , Bigot, Pierre , Carrouget, Julie |
Editeur | Springer |
Type | Article scientifique dans une revue à comité de lecture |
Année | 2018 |
Langue | Anglais |
Date | Septembre 2018 |
Numéro | 9 |
Pagination | 1455-1460 |
Volume | 36 |
Titre de la revue | World Journal of Urology |
ISSN | 1433-8726 |
Mots-clés | Adult, Aged, Aged, 80 and over, Cholinergic Antagonists, Drug resistance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Tibial Nerve, Time Factors, Transcutaneous Electric Nerve Stimulation, Treatment Outcome, Urinary Bladder, Overactive |
Résumé en anglais | PURPOSE: To evaluate long-term use, efficacy and tolerability of transcutaneous tibial nerve stimulation (TTNS) in the treatment of refractory overactive bladder (OAB). METHODS: We performed a prospective observational study and included all patients treated in a single center for OAB persisting after first-line anticholinergic treatment, with ≥ 24 months follow-up. The protocol consisted of daily stimulation at home. The primary outcome was treatment persistence. Amelioration was defined as an improvement in urinary symptom profile (USP) score. RESULTS: We assessed 84 consecutive patients. After a mean follow-up of 39.3 months and a mean treatment use of 8.3 months, almost two-thirds of patients (71.8%) had discontinued TTNS. Treatment continuation was > 12 months for 28 patients (33.3%) and > 18 months for 16 patients (19%). TTNS was successful following 3 months of treatment in 60 (71%) patients. Mean USP score stayed significantly lower than baseline until 12 months of treatment, but was not significant anymore after 18 months. Discontinuation therapy reasons were a lack of sufficient symptom relief for 59 (70%) patients, compliance difficulty for 5 (6%) patients and becoming asymptomatic for 6 (8%) patients. No serious adverse events occurred. CONCLUSIONS: The present study confirms the utility of TTNS as a treatment option for patients with resistant OAB. In the long-term use, few patients continued with therapy, mostly because of a decreased effectiveness with time. |
URL de la notice | http://okina.univ-angers.fr/publications/ua19659 |
DOI | 10.1007/s00345-018-2296-5 |
Lien vers le document | https://link.springer.com/article/10.1007%2Fs00345-018-2296-5 |
Titre abrégé | World J Urol |
Identifiant (ID) PubMed | 29633085 |